The established ceRNA network and prognostic model lays the foundation for future basic and clinical investigations, and MIR99AHG might be identified as a novel molecular target for accurate diagnosis, targeted therapy, and immunotherapy of GC patients. Here, MIR99AHG is linked to gastric cancer.